PIK3CG and neoplasm: Given that the combination of PI3Kα-specific inhibition plus PTX failed to sensitize PyMT tumors for ICI therapy, we postulated that it might be necessary to also inhibit other PI3K isoforms (e.g., PI3Kγ) based on the findings that PI3Kγ or pan-PI3K inhibition can shift the tumor immune microenvironment to one that is anti-tumor by directly affecting macrophage phenotype [10,16].